Last reviewed · How we verify
Rapid-tapering glucocorticoids + Inebilizumab
Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), reduces pathogenic B cell and autoantibody production, combined with rapid-tapering glucocorticoids to suppress acute inflammation in autoimmune disease.
Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), reduces pathogenic B cell and autoantibody production, combined with rapid-tapering glucocorticoids to suppress acute inflammation in autoimmune disease. Used for Anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
At a glance
| Generic name | Rapid-tapering glucocorticoids + Inebilizumab |
|---|---|
| Sponsor | Tianjin Medical University General Hospital |
| Drug class | Monoclonal antibody + Glucocorticoid combination |
| Target | BDCA-2 (on pDCs) + Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Autoimmune disease |
| Phase | Phase 3 |
Mechanism of action
Inebilizumab binds to BDCA-2 on plasmacytoid dendritic cells, depleting these cells and reducing their production of type I interferons and support for autoreactive B cells. Glucocorticoids provide rapid anti-inflammatory and immunosuppressive effects during the acute phase. Together, this combination targets both innate immune activation and adaptive autoimmune responses.
Approved indications
- Anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD)
Common side effects
- Infection (including serious infections)
- Hyperglycemia / glucose intolerance
- Hypertension
- Mood disturbances
- Immunosuppression-related complications
Key clinical trials
- Inectolizumab With Steroid Optimization in Newly Treated NMOSD (NA)
- Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: